Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. [Phase 2]

View source ↗

Summary

Phase 2 trial update of sorafenib tosylate in malignant mesothelioma has completed (status: COMPLETED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biphasic Mesothelioma
• Epithelioid Mesothelioma
• Malignant Mesothelioma
• Sarcomatoid Mesothelioma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Epithelial Mesothelioma, Recurrent Malignant Mesothelioma | Phase 2 | Status: COMPLETED